Navigation Links
KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody
Date:12/10/2013

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced preliminary results of an ongoing multi-center Phase 1 study of KB004, an anti-EphA3 monoclonal antibody (mAb), which the company is developing as a treatment for hematologic malignancies. Forty-four patients with refractory disease or who were unfit for chemotherapy have been enrolled in the dose escalation portion of the study.  The experimental patient-targeted therapeutic has been well tolerated, with initial evidence of clinical activity.

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

Preliminary results of the study were presented yesterday by lead investigator, Jeffrey E. Lancet, M.D. of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida at the 55th American Society of Hematology Annual Meeting and Exhibition (ASH), held this week in New Orleans, Louisiana.

"We are encouraged by the results seen with KB004 to date, which has been well-tolerated at doses up to 190 mg, with mild to moderate transient infusion reactions the most common toxicity," said Dr. Lancet. "There are some signs of activity as well, including a patient with relapsed acute myeloid leukemia (AML) who had sustained remission for over 1 year."

Escalating doses of KB004 were administered as a 1 or 2 hour infusion on days 1, 8, and 15 of a 21 day cycle at incremental doses of 20, 40, 70, 100, 140, 190 and 250 mg and will thereafter increase at 33% increments up to a planned maximum of 700 mg. The primary study objective is to determine a maximum tolerated dose, which has not yet been reached. Secondary objectives included evaluation of pharmacokinetics, imm
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
2. Wyss Institute at Harvard University announces election of 2 faculty to Natl Academy of Inventors
3. Reproductive Health Matters announces publication of its latest themed issue: New development paradigm
4. Afterburn Fuel Review Announces the Launch of its New and Informative Website
5. VaxTrac Announces Continued Support for Expansion of Biometric-based Mobile Vaccine Registry Programs in Benin
6. AIBS announces winners of Faces of Biology photo competition
7. NERC announces the winner of its first photo and essay competition
8. Elsevier announces the launch of open access journal: Current Plant Biology
9. AVS Announces Its Major Award Winners of 2013
10. The Association for Molecular Pathology announces highlights of Phoenix meeting
11. EMBO announces the launch of EMBO Press
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... the shortest distance between two points is a straight ... have been taking the familiar axiom to heart. ... to be intense, with each racing for the chance ... species, sperm form cooperative groups that allow them to ... A new study, conducted by Heidi Fisher, a post-doctoral ...
(Date:7/30/2014)... San Antonio Life Sciences Institute (SALSI), a joint venture ... and The University of Texas Health Science Center at ... Initiative Pilot Program. The winners, Emily Boice from UTSA ... receive $25,000 for their project titled, "Novel engineered ferritins ... environment." , Boice and Huang,s research is focused on ...
(Date:7/30/2014)... of $1 million from the Cornelia Cogswell Rossi Foundation ... Center. , The newly established Connie Cogswell ... develop a greater breadth and depth of knowledge of ... pace of research to improve human health. , The ... the Laboratory and its external partners, supporting research to ...
Breaking Biology News(10 mins):When cooperation counts 2When cooperation counts 3Rossi Foundation pledges $1M for JAX neurobehavioral research center 2
... New Zealand snail and its worm parasite makes sex ... in the absence of parasites, say Indiana University Bloomington ... week,s Current Biology . The scientists, report ... of sex, which suggests sexual reproduction allows host species ...
... external skeletons that appear to change colors as the ... for something else--providing a blueprint for materials that reflect ... Scientists at the Georgia Institute of Technology in Atlanta ... light-reflecting properties of the cells that make up their ...
... -- Experiencing chronic stress day after day can produce wear ... have a detrimental effect on learning and emotion. However, ... learning and memory. Researchers at the University at Buffalo ... that acute stress can produce a beneficial effect on learning ...
Cached Biology News:Parasitic worms make sex worthwhile 2Parasitic worms make sex worthwhile 3What scientists know about jewel beetle shimmer 2Short stressful events may improve working memory 2
(Date:7/30/2014)... 30, 2014 BCC Research ( http://www.bccresearch.com ... for Enzymes in Industrial Applications , the global market ... $7.1 billion by 2018, registering a five-year compound annual ... to be recorded in the detergent enzyme segment with ... Enzyme technology has influenced almost every sector of industrial ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
(Date:7/30/2014)... , July 30, 2014   Epic Sciences, Inc. ... develops novel diagnostics to personalize and advance the treatment ... Gregory T. Lucier as chairman of Epic,s ... CEO of Life Technologies (formerly Invitrogen). Mr. Lucier joins ... commercializes its circulating rare cell analysis platform with special ...
(Date:7/30/2014)... July 30, 2014 NCERC at ... will present his findings on corn stover pretreatment ... this week in Washington, D.C. , “Arun’s ... conference is a testament to the success of ... said. “Thanks to the foresight and vision of ...
Breaking Biology Technology:Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... Aug. 7 SGX Pharmaceuticals,(Nasdaq: SGXP ) today announced ... 30, 2008. For the three months ended June 30, 2008, ... of $7.2 million. For,the six months ended June 30, 2008, ... The revenue in the six month period includes $10.8,million of ...
... SOUTH SAN FRANCISCO, Calif., Aug. 7 Anesiva,Inc. (Nasdaq: ... the second quarter and six months ended June 30, ... advance for Anesiva as we,introduced Zingo(TM) in the U.S. ... executive officer. "In addition, I,m pleased,to report that our ...
... Chromos Molecular,Systems Inc. ("Chromos" or the "Company") announced ... (the "Arrangement Agreement") dated,August 6, 2008 with, among ... Chromos, and Modatech Systems Inc. ("Modatech"),pursuant to which ... effect a plan,of arrangement (the "Arrangement") under section ...
Cached Biology Technology:SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 2SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 3SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 4SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 5SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 6SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 7SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 8SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 9Anesiva Announces Second Quarter 2008 Financial Results and Update 2Anesiva Announces Second Quarter 2008 Financial Results and Update 3Anesiva Announces Second Quarter 2008 Financial Results and Update 4Anesiva Announces Second Quarter 2008 Financial Results and Update 5Anesiva Announces Second Quarter 2008 Financial Results and Update 6Anesiva Announces Second Quarter 2008 Financial Results and Update 7Anesiva Announces Second Quarter 2008 Financial Results and Update 8Chromos enters into an Arrangement Agreement 2Chromos enters into an Arrangement Agreement 3
... is a molecular screening, low melting point ... sieving. It is recommended for separation of ... such as PCR products. Micro ABgarose is ... not recommended for blotting techniques. At a ...
Rabbit polyclonal to L Kynurenine ( Abpromise for all tested applications). Antigen: Synthetic peptide L Kynurenine conjugated to a protein carrier. Entrez Gene ID: 8942 Swiss Protein ID...
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
Sheep polyclonal to Salmonella Thomasville ( Abpromise for all tested applications). Antigen: Native Salmonella thomasville...
Biology Products: